# BPC-157: Research Overview — Prime Research Peptides > A literature summary of BPC-157 (Body Protection Compound 157): angiogenesis mechanism, rodent tissue-repair studies, pharmacokinetics, the thin human evidence file, and regulatory status. A synthetic fifteen-amino-acid peptide whose repair effects in animal models are tied to new blood-vessel growth — and whose human evidence is three small pilots, with the word 'small' doing a lot of work. ## The short version BPC-157 stands for Body Protection Compound 157. It is a synthetic fifteen-amino-acid peptide derived from a portion of a protein found in human gastric juice. In animal studies — overwhelmingly in rats — it has been shown to accelerate healing of tendons, gut lining, muscle, and nerve tissue. The mechanism that researchers return to most consistently is angiogenesis: the peptide appears to make blood-vessel cells more responsive to the body's own signal for growing new vessels, which brings oxygen and nutrients into an injury [25]. Here is the honest context. Almost all of this evidence comes from animals. A 2025 narrative review counted only three pilot studies of BPC-157 in humans and concluded that rigorous, large-scale trials are lacking and that the compound should be treated as investigational [23]. The first controlled intravenous safety data in humans involved two people [22]. This puts BPC-157 at the far preclinical end of this desk's evidence spectrum — further from approval than retatrutide (Phase 3), much further than tesamorelin (narrow FDA approval), and in an entirely different league from the large-trial evidence behind semaglutide and tirzepatide. BPC-157 is not an approved drug anywhere. It is prohibited in sport by WADA. It was placed by the FDA in 2023 in a category of substances not eligible for pharmacy compounding under 503A, pending further evaluation. ## What it is BPC-157 is a stable gastric pentadecapeptide — fifteen amino acids long — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The "stable gastric" designation means the sequence is derived from a cytoprotective protein found in gastric juice and resists breakdown in the stomach — a property that makes it useful in oral delivery research. It is also catalogued in the research literature under the designations PL 14736, PLD-116, PL-10, and the research designation Bepecin. The molecular formula is C62H98N16O22. It is synthesized rather than extracted — you cannot get BPC-157 from food, gastric juice, or a natural source in pharmacologically relevant amounts. It is a research peptide with no approved drug or supplement status in any major jurisdiction and no established human therapeutic indication. ## How it works The best-characterized mechanism is angiogenesis — the formation of new blood vessels. A 2017 study across multiple model systems (chick chorioallantoic membrane, rat hindlimb ischemia model, and human vascular endothelial cells) showed that BPC-157 increased expression of the VEGFR2 receptor and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS signaling pathway; blocking receptor internalization blocked the effect. In the ischemic muscle model, it accelerated blood-flow recovery [25]. Beyond the vascular mechanism, the peptide is described in the animal literature as a brain-gut-axis modulator that affects serotonin and dopamine systems and engages cell-migration pathways (FAK-paxillin), Egr-1/NAB2 signaling, and JAK-2 pathways. In tendon cells specifically, it has been reported to sensitize the growth-hormone receptor — a mechanism proposed to explain some of its tissue-building effects in musculoskeletal models. Mechanism targets: VEGFR2 (KDR), endothelial nitric oxide synthase (eNOS), growth hormone receptor (tendon fibroblasts), FAK-paxillin complex. The throughline is a peptide described as nudging multiple repair-related signals rather than hitting a single defined target — which makes mechanistic interpretation complex and independent replication important. ## What the research shows **Gastric cytoprotection (rats, 2004).** BPC-157 reduced gastric ulcer area and accelerated ulcer healing in Wistar rats; intramuscular delivery outperformed intragastric delivery; ulcer-formation inhibition ratios of approximately 46-66% at higher doses [26]. **Angiogenesis mechanism (multiple models, 2017).** BPC-157 increased vessel density in a chick membrane model and in human vascular endothelial cells, and accelerated blood-flow recovery in a rat hindlimb ischemia model via the VEGFR2/Akt/eNOS pathway [25]. **Pharmacokinetics (rats and dogs, 2022).** The first formal PK/ADME characterization found linear pharmacokinetics, elimination half-life under 30 minutes, intramuscular bioavailability of approximately 14-19% in rats and 45-51% in dogs, and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism. The short half-life means the intact peptide does not linger in the bloodstream [24]. **First-in-human safety pilot (2025).** Intravenous BPC-157 was given to two healthy adults (a 58-year-old male and a 68-year-old female) at doses up to 20 mg. Both tolerated it with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [22]. Two people is the sample size. This was a safety signal, not an efficacy trial. **2025 narrative review.** A Curr Rev Musculoskelet Med review concluded that human data are extremely limited (only three pilot studies), rigorous large-scale trials are lacking, BPC-157 should be treated as investigational, and popular claims about weight loss or muscle building are not supported by the published evidence [23]. ## Reported effects, cautions and safety **Anecdotal community reports (not clinical evidence, not verified):** The most common reason people in research-use communities describe trying BPC-157 is tendon, ligament, and joint injuries — stubborn problems such as tennis elbow or rotator-cuff strains that they say improve within the first few weeks. Joint stiffness and pain are also frequently described as easing. Gut and digestive symptoms (bloating, cramping, urgency) are another common reported use, drawing on the compound's gastric origins. A smaller group reports faster skin and wound healing, better sleep, or a general sense of reduced inflammation. The most common adverse reports are injection-site redness, stinging, or a small bump (usually brief and mild); nausea or mild stomach upset in the first days; fatigue in the first week; headaches; and occasionally dizziness after dosing. These are **anecdotal, not clinical evidence** — personal reports from unmonitored research-use contexts. **Cautions from the clinical and mechanistic literature:** - *Extremely thin human evidence*: Three pilot studies, no large controlled trials, genuine unknowns about benefit and risk in humans [23]. - *Single-research-group concentration*: A large share of the foundational animal literature comes from one research group and its collaborators (Sikiric and colleagues); independent replication is limited and newer reviewers flag this explicitly [23]. - *No approved drug status anywhere; unregulated supply*: BPC-157 is sold through non-regulated research channels; product identity, purity, and dose are unverified outside formal studies. - *WADA prohibited*: Banned at all times under the S0 non-approved-substances category. Direct concern for any competitive athlete. - *Pro-angiogenic mechanism raises a theoretical cancer concern*: Strong VEGFR2-pathway activation is also how tumors recruit blood supply. This is mechanism-based reasoning, not a human finding, but it is a reason cited for caution in people with active or suspected malignancy. - *Possible serotonin interaction*: Animal work shows BPC-157 alters brain serotonin activity; a mechanism-based concern about combining it with serotonin-affecting medicines exists, though no human interaction study has been done. - *Growth-hormone receptor sensitization*: Any agent that amplifies growth pathways carries theoretical questions about long-term or unwanted tissue growth; no long-term human safety data exist to settle this. ## Where it fits BPC-157 is at the preclinical end of this desk's evidence spectrum — the largest body of evidence, and yet almost none of it in humans. Three decades of animal work have built an internally consistent story of repair through angiogenesis; three small human pilots have not broken that story but have not yet confirmed it at scale either [23]. The comparison to look at is the distance between here and where semaglutide sits. Semaglutide has a 17,604-person cardiovascular outcomes trial [3]. BPC-157 has a two-person safety pilot [22]. Both are peptides. The word "peptide" does not carry an evidence guarantee. This is not a reason to dismiss the preclinical signal — it is a reason to read it correctly, as animal-model evidence that still needs to pass through rigorous human trials to become medicine. See how BPC-157 compares to all four other compounds on the [evidence map](/compare). ![BPC-157 research illustration](/images/bpc-157.webp) --- An independent literature desk mapping the evidence from regulatory approval to first-in-human pilot — a spectrum, not a sales pitch.